Merck
MRK
#41
Rank
$354.80 B
Marketcap
$143.81
Share price
-1.03%
Change (1 day)
59.56%
Change (1 year)

P/E ratio for Merck (MRK)

P/E ratio as of October 2026 (TTM): 114

According to Merck's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 113.636. At the end of 2025 the company had a P/E ratio of 14.4.

P/E ratio history for Merck from 2001 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202514.4-0.33%
202414.4-97.87%
20236793674.95%
202218.034.71%
202113.4-44.9%
202024.227.46%
201919.0-25.19%
201825.4-44.27%
201745.6116.87%
201621.0-11.64%
201523.8152.83%
20149.42-58.32%
201322.686.02%
201212.16.11%
201111.4

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
29.6-73.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
21.2-81.36%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
37.0-67.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
31.0-72.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
38.5-66.14%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
25.1-77.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
21.4-81.19%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
13.5-88.09%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
14.8-87.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Teva Pharmaceutical Industries
TEVA
62.4-45.09%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.